102
value of PCNA labeling index in primary operable breast cancer. Oncol Rep,
v.5(3):641-4, 1998.
HORIQUCHI J., IINO Y., TAKEY H., MORISHITA Y, NAKAJIMA T. Expression of
proliferating cell nuclear antigen in invasive ductal carcinoma of the breast. Jpn
J Clin Oncol, v.24(2):79-84, 1994.
HUANG P., OLIFF A. Signaling pathways in apoptosis as potencial targets for
cancer therapy. Trends Cell Biol, Cambridge, v.11, p.343-348, 2001.
INGVARSSON S. Breast cancer: introduction. Cancer Biol, v.11, p.323-326, 2001.
ISOLA J., KALLIONIEMI O.P., KORTE J.M., WAHLSTROM T., AINE R., HELLE
M., HELIN H. Steroid receptors and Ki-67 reactivity in ovarian cancer and in
normal ovary: correlation with DNA flow cytometry, biochemical receptor assay,
and patient survival. J Pathol, 162, 295-301, 1990.
JACQUEMIER J.D., PENAULT-LLORCA F.M., BERTUCCI F., SUN Z.Z.,
HOUVENAEGHEL G.F., GENEIX J.A., PUIG B.D., BARDOU V.J., HASSOUN
J.A., BIRNBAUM D., VIENS P.J. Angiogenesis as a prognostic marker in breast
carcinoma with conventional adjuvant chemotherapy: a multiparametric and
immunohistochemical analysis. Journal of Patholology, v.184: 130-135, 1998.
JERICÓ M.M., SCHEFFER K.C. Aspectos epidemiológicos dos cães obesos na
cidade de São Paulo. Clin Vet, n.37, p. 25-9, 2002.
KALOGERAKI A., TZARDI M., DATSERIS G., KANAVAROS P., KARVELAS C.,
CHALKIADAKIS G., TSIFTSIS D., DELIDES G. Proliferating cell nuclear
antigen (PCNA) expression in patients with breast carcinoma in comparison to
patients with benign breast diseases. In vivo, v.8(6):1053-6, 1994.
KATO T., KAMEOKA S., KIMURA T., NISHIKAWA T., KOBAYASHI M. C-erbB-2
and PCNA as prognostic indicators of long-term survival in breast cancer.
Anticacer Res, v.22(2B):1097-103, 2002.
KATO T., KIMURA T., ISHII N., FUJII A., YAMAMOTO K., KAMEOKA S.,
NISHIKAWA T., KASAJIMA T. The metodology of quantitation of microvessel
density and prognostic value of neovascularization associated with longterm
survival in japanese patients with breast cancer. Breast Cancer Res, Treat.;
53: 19-31, 1999.